RE: Alan Whitehead, MP22 Apr 2020 15:37
I might be wrong but I think the company want to keep the trials in their control for obvious reasons. The notice on tehir website clearly indicates they have interest from outside of the trial. I think this will fly once our trials are completed and the governement will be all over it.
"Access to SNG001 to treat individuals outside clinical trials
On the 18th March Synairgen announced its plans to initiate a pilot clinical trial of SNG001 in COVID-19 patients. The trial will provide data on the efficacy of inhaled interferon beta in the treatment of ambulatory and hospitalised patients infected with SARS-CoV-2. Since the announcement, we have received a number of requests for SNG001 supplies to treat individuals outside the trial. As SNG001 is an experimental drug, untested as to safety and efficacy in this patient group, we regret that we are unable to fulfil any such request at this time. Synairgen’s team is working very hard to establish these measures in a well-controlled environment as quickly as possible."